Single center experience with oxybutynin transdermal system (patch) for management of symptoms related to non-neuropathic overactive bladder in children: an attractive, well tolerated alternative form of administration.
OBJECTIVE
Oxybutynin is the current gold standard drug for management of overactive bladder (OAB) in children, but can have significant side effects or be difficult to administer in multiple daily doses. Herein, we report our experience with transdermal oxybutynin patch (TOP) as an alternative in a selected patient population without neuropathic compromise.


METHODS
Consecutive patients assessed in a pediatric urology clinic over a 1-year period, diagnosed with OAB with minimum follow-up of 3 months, were included. TOP starting dose was 3.9 mg/day based on product design (Oxytrol). Demographics and outcomes data were retrospectively collected. Symptomatic response was defined as improvement or resolution of lower urinary tract symptoms.


RESULTS
35 children met inclusion criteria (mean age 8 years, range 4-16). Overall, 97% reported good symptom response. The main side effect was skin irritation at TOP site (35%), leading to discontinuation in 20%. There were no reports of other significant side effects. Mean bladder capacity increased from 104 ml to 148 ml at follow-up.


CONCLUSIONS
Our data suggest that TOP is a viable alternative for children with non-neuropathic OAB who do not tolerate other formulations of oxybutynin. These findings highlight the potential benefit of transdermal drug delivery in the pediatric setting.
Division of Urology, The Hospital for Sick Children, Department of Surgery, The University of Toronto, 555 University Avenue, Toronto, Ontario M5G 1X8, Canada. Electronic address: glea0058@umn.edu.
Joseph M
JM
Gleason
Division of Urology, The Hospital for Sick Children, Department of Surgery, The University of Toronto, 555 University Avenue, Toronto, Ontario M5G 1X8, Canada.
Catherine
C
Daniels
Division of Urology, The Hospital for Sick Children, Department of Surgery, The University of Toronto, 555 University Avenue, Toronto, Ontario M5G 1X8, Canada.
Katharine
K
Williams
Division of Urology, The Hospital for Sick Children, Department of Surgery, The University of Toronto, 555 University Avenue, Toronto, Ontario M5G 1X8, Canada.
Abby
A
Varghese
Division of Urology, The Hospital for Sick Children, Department of Surgery, The University of Toronto, 555 University Avenue, Toronto, Ontario M5G 1X8, Canada.
Martin A
MA
Koyle
Division of Urology, The Hospital for Sick Children, Department of Surgery, The University of Toronto, 555 University Avenue, Toronto, Ontario M5G 1X8, Canada.
Darius J
DJ
Bägli
Division of Urology, The Hospital for Sick Children, Department of Surgery, The University of Toronto, 555 University Avenue, Toronto, Ontario M5G 1X8, Canada.
Joao L
JL
Pippi Salle
Division of Urology, The Hospital for Sick Children, Department of Surgery, The University of Toronto, 555 University Avenue, Toronto, Ontario M5G 1X8, Canada. Electronic address: armando.lorenzo@sickkids.ca.
Armando J
AJ
Lorenzo
D000279:Administration, Cutaneous; D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D008297:Male; D008333:Mandelic Acids / Q000008:administration & dosage* / Q000009:adverse effects; D018727:Muscarinic Antagonists / Q000008:administration & dosage* / Q000009:adverse effects; D012189:Retrospective Studies; D057968:Transdermal Patch; D016896:Treatment Outcome; D053201:Urinary Bladder, Overactive / Q000188:drug therapy* / Q000209:etiology
D008333:Mandelic Acids; D018727:Muscarinic Antagonists; C005419:oxybutynin
Children; Incontinence; Overactive bladder; Oxybutynin; Urgency